本文由小咖机器人翻译整理

期刊来源：Nat Med

原文链接：https://doi.org/10.1038/s41591-023-02754-1

摘要内容如下：

二线大B细胞淋巴瘤的3期Zuma-7试验证明，抗CD19 CAR T细胞疗法（Axicabtagene Ciloleucel（Axi-Cel））优于标准治疗（SOC；挽救化疗后造血移植）（NCT03391466）。在这里，我们提出了一个预先指定的探索性分析，研究治疗前肿瘤特征与Axi-Cel和SOC疗效之间的关系。B细胞基因表达标记（GES）和CD19表达与Axi-Cel无事件生存率的提高显著相关（B细胞GES的P=0.0002；CD19表达的P=0.0165）而不是SOC（B细胞GES的P=0.9374；CD19表达的P=0.5526）。与SOC相比，Axi-Cel显示出更高的无事件生存率，而与B细胞GES和CD19表达无关（B细胞GES高，P=8.56×10-9；对于B细胞GES低，P=0.00 19；CD19基因高表达P=3.85×10-9；CD19基因P=0.0017（低）。恶性细胞中的低CD19表达与由免疫抑制间质和髓系基因组成的肿瘤GES相关，突出了恶性细胞特征和免疫环境之间的相互关系，显著影响Axi-Cel的结果。肿瘤负荷、乳酸脱氢酶和细胞来源对SOC的影响大于AXI-CEL结果。与Axi-Cel预后改善相关的T细胞活化和B细胞GES随着治疗次数的增加而减少。这些数据突出了对Axi-Cel和SOC耐药机制的差异，并支持对Axi-Cel进行早期干预。

英文原文如下：

Abstracts

The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care (SOC; salvage chemotherapy followed by hematopoietic transplantation) ( NCT03391466 ). Here, we present a prespecified exploratory analysis examining the association between pretreatment tumor characteristics and the efficacy of axi-cel versus SOC. B cell gene expression signature (GES) and CD19 expression associated significantly with improved event-free survival for axi-cel (P = 0.0002 for B cell GES; P = 0.0165 for CD19 expression) but not SOC (P = 0.9374 for B cell GES; P = 0.5526 for CD19 expression). Axi-cel showed superior event-free survival over SOC irrespective of B cell GES and CD19 expression (P = 8.56 × 10-9 for B cell GES high; P = 0.0019 for B cell GES low; P = 3.85 × 10-9 for CD19 gene high; P = 0.0017 for CD19 gene low). Low CD19 expression in malignant cells correlated with a tumor GES consisting of immune-suppressive stromal and myeloid genes, highlighting the inter-relation between malignant cell features and immune contexture substantially impacting axi-cel outcomes. Tumor burden, lactate dehydrogenase and cell-of-origin impacted SOC more than axi-cel outcomes. T cell activation and B cell GES, which are associated with improved axi-cel outcome, decreased with increasing lines of therapy. These data highlight differences in resistance mechanisms to axi-cel and SOC and support earlier intervention with axi-cel.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。

现在购买可享受最大优惠（买一年送三个月，买两年送一年），2024年2月10日起将不再享有该优惠。